Key facts
- Eastenova’s last known valuation is $206.8M (Mar 2025).
- It has raised $28.0M; the latest was IPO in May 2025.
- Notable investors include Shenzhen Capital Group, Chengdu Jiaozi Financial Holding Group, China Medical System, SUNNOVO, Shenzhen HTI Group.
- Status: In IPO Registration.
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Eastenova
- ·The full record, as it builds
Funding rounds
No funding rounds for Eastenova are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eastenova
Developer of regenerative medical devices and foods to be used in various regenerative medical treatments. The company's therapeutics provide regenerative support in repairing lost cells and tissue, enabling physicians to prescribe effective healing treatments.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 185
- Website
- dfyanmei.com/
- Ownership
- In IPO Registration
Eastenova doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eastenova shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eastenova in its N-PORT filings yet. We sweep new filings monthly.